18 February 2023>: Clinical Research
Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease
Tomislav Jukic 1CDEF , David Drobne 2ABCDE , Sasa Pusavec 3BF , Alojz Ihan 3AE , David Stubljar 4ACDE* , Andrej Starc 5DEDOI: 10.12659/MSM.939084
Med Sci Monit 2023; 29:e939084
Table 1 Basic characteristics of patients whose samples were included in analysis.
All patients (N=32) | |
---|---|
Gender | |
Male/Female | 15 (46.9%)/17 (53.1%) |
Age [years] | 27.5 |
IBD phenotype | |
Crohn’s disease | 19 (59.4%) |
Ulcerative colitis | 13 (40.6%) |
Location | |
L1: terminal ileal/limited cecal disease | 2 (5.2%) |
L2: colonic | 19 (59.4%) |
L3: ileocolonic | 11 (34.2%) |
L4: upper disease | 0 |
Years from diagnosis till start of IFX | |
0–5 | 11 (34.2%) |
5–10 | 9 (28.1%) |
>10 | 12 (37.5%) |